Dauntless Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development of specialty drugs. Our innovative one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure, leading to lower costs, shorter timelines and higher returns. Unlike a traditional biotech company which holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets, Dauntless uses a one-asset, one-company model where each asset is held in a separate holding company. Dauntless manages the development of each asset and employs expert consultants who specialize in the unique requirements of a given asset.
Latest funding size
Time since last funding
|about 1 month|
|Canaan Partners, Sofinnova Ventures|